UNSPSC 51401511: Ethyl carfluzepate

This classification denotes a benzodiazepine with the molecular formula C20H17ClFN3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 36M73UIK01, chemically known as 1h-1,4-benzodiazepine-3-carboxylic acid, 2,3-dihydro-7-chloro-5-(2-fluorophenyl)-1-((methylamino)carbonyl)-2-oxo-, ethyl ester but generally known as ethyl carfluzepate, which bears US NIH Compound Identifier 68856. European Medicines Agency schedules Ethyl carfluzepate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07286MIG.

UNSPSC 51401511 Ethyl carfluzepate is a Commodity code with misalignment between its nominal scope and the recent state and local opportunities posted under it. The source shows minimal recent activity directly tied to ethyl carfluzepate procurement; instead, the opportunities tagged to this code involve naloxone distribution, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical sourcing across cooperative purchasing frameworks. State and local buyers using this code appear to be procuring pharmaceutical products and pharmacy benefit administration support, but the recent solicitations do not isolate ethyl carfluzepate as a discrete line item or focus area. The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance administering contracts for participating state and local facilities across multiple states including Oregon).

Activity concentrates in Florida, Texas, and the Upper Midwest through cooperative purchasing arrangements. The most recent opportunity is Seminole County's IFB60459723LAS, posted June 30, 2026, with a response deadline of July 26, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries; the procurement requires electronic bidding and includes E-Verify compliance and specific insurance coverage mandates. The Texas HHS Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, signaling state interest in restructuring pharmacy benefit administration outside traditional PBM and GPO channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released RFP S1070000015802 in January 2026 with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with contract effectiveness set for July 1, 2026. The code shows sparse direct targeting of ethyl carfluzepate itself; vendors evaluating this code should verify whether recent opportunities under it align with their specific product offerings or represent broader pharmaceutical procurement activity.